Oral semaglutide cardiovascular outcomes reported in SOUL
Awaiting primary-source check
The SOUL trial reported a reduction in major adverse cardiovascular events among adults with type 2 diabetes at high cardiovascular risk. Cardiovascular outcome trials matter more than weight figures for judging long-term benefit, and they take years to run.
Told first, next time
This story reached you late. A short email when a licence changes, a safety alert lands, or a trial reports. No selling, no advertising, no sharing your address.
What this is. A dated, sourced note on something that changed. Peptide Register is an independent reference: it sells nothing, carries no advertising, and takes no money from any company selling any compound it covers. This is not medical advice. If a change affects a medicine you are prescribed, speak to your doctor or pharmacist rather than acting on something you read here.